Following a difficult year for aquaculture health, nutrition and genetics business Benchmark, share prices have been on a downward trend since Dec. 19, in the wake of the release of its financial performance.

Adjusted earnings before interest, tax, depreciation and amortization (EBITDA) for Benchmark's continuing operations is down by 37 percent to £12.1 million (€14.2 million/$15.8 million), while operating profit declined by 75 percent to £3.6 million (€4.2 million/$4.7 million).

Benchmark's share price is in decline.